Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Marijuana Abuse 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 47Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31trastuzumab deruxtecan 27Specimen Handling 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18Biopsy 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Cannabidiol × Clear all
NCT06731894 2025-12-05

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

City of Hope Medical Center

Phase 2 Recruiting
120 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡